Dermira is a privately held specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients. Dermira's portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates, Cimzia (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis, DRM04, a topical treatment for hyperhidrosis, and DRM01, a topical sebum inhibitor for the treatment of acne.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/19/14 | $51,000,000 | Series C |
Aisling Capital Apple Tree Partners Rock Springs Capital Sabby Capital | undisclosed |
